Device Trial Radar · NCT03820947
VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial
Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
506
Actual
Start
Feb 5, 2020
Primary completion
Jun 12, 2024
Study completion Nov 10, 2025
Sponsor
- Lead sponsor
- Medtronic EndovascularPublic (MDT)
- Sponsor type
- Industry
- First posted
- Jan 29, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Global, Post-Market, Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal™ Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early and Advanced Stage Superficial Venous Disease
Conditions
- Venous Reflux
Interventions
VenaSeal™ SystemDevice
The VenaSeal™ System is the non-tumescent, non-thermal, non-sclerosant device that uses a proprietary medical adhesive delivered endovenously to close the vein.
Endothermal Ablation (ETA)Device
ETA includes EVLA that uses laser or RFA that uses radiofrequency heating to close the vein. Heat is applied in both EVLA and RFA therapies to close the vein. Subject can be treated with either EVLA or RFA if randomized to ETA arm per site's standard practice.
Surgical StrippingProcedure
Surgical stripping involves stripping (removal) of the diseased vein via surgical procedures.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Randomized Study VenaSeal™ System Versus Endothermal Ablation (ETA): Primary Endpoint: Peri-procedural Patient Satisfaction as Measured by a Validated, Patient-centered Venous Treatment Satisfaction Questionnaire (VenousTSQe) at 30 Days.Time frame: 30 days
- Randomized Study VenaSeal™ System Versus Surgical Stripping: Primary Endpoint: Peri-procedural Patient Satisfaction as Measured by a Validated, Patient-centered Venous Treatment Satisfaction Questionnaire (VenousTSQe) at 30 Days.Time frame: 30 days
- Randomized Study VenaSeal™ System Versus Endothermal Ablation (ETA): Primary Endpoint: Patient Satisfaction as Measured by a Validated, Patient-centered Venous Treatment Satisfaction Questionnaire (VenousTSQs) at 30 Days.Time frame: 30 days
4 more outcomes with a free account
Locations
32 sites in 10 countries. Site status is shown where the registry gives one.
Yavapai Regional Medical Center
Prescott Valley, Arizona
PIMA Heart and Vascular
Tucson, Arizona
Valley Vascular Surgical Associates
Fresno, California
29 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.